Artemis Investment Management LLP grew its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 94,444 shares of the medical research company’s stock after purchasing an additional 546 shares during the period. Artemis Investment Management LLP’s holdings in Thermo Fisher Scientific were worth $17,866,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the business. Amalgamated Bank lifted its stake in shares of Thermo Fisher Scientific by 57.0% in the 2nd quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after acquiring an additional 16,308 shares during the last quarter. Mutual of America Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 2.1% in the 2nd quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock valued at $8,327,000 after acquiring an additional 977 shares during the last quarter. Mitchell Capital Management Co. lifted its stake in shares of Thermo Fisher Scientific by 40.3% in the 2nd quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock valued at $7,841,000 after acquiring an additional 12,910 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its stake in shares of Thermo Fisher Scientific by 0.9% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock valued at $101,317,000 after acquiring an additional 5,213 shares during the last quarter. Finally, San Francisco Sentry Investment Group CA bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $1,451,000. 85.32% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have commented on the company. Deutsche Bank AG set a $226.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. Leerink Swann upped their price target on Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a research report on Monday, October 9th. Cowen and Company reaffirmed an “outperform” rating and set a $220.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Finally, Barclays PLC reaffirmed an “overweight” rating and set a $215.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $205.71.
Thermo Fisher Scientific Inc (TMO) opened at $192.75 on Thursday. The stock has a market capitalization of $77,364.04, a P/E ratio of 21.20, a P/E/G ratio of 1.77 and a beta of 1.08. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $201.20. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The firm’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.03 EPS. equities analysts anticipate that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.15 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.31%. Thermo Fisher Scientific’s payout ratio is 10.19%.
COPYRIGHT VIOLATION WARNING: This piece was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://ledgergazette.com/2017/11/23/thermo-fisher-scientific-inc-tmo-shares-bought-by-artemis-investment-management-llp.html.
In related news, Director C Martin Harris sold 360 shares of the firm’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total value of $65,149.20. Following the transaction, the director now directly owns 5,312 shares of the company’s stock, valued at approximately $961,312.64. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the transaction, the chief executive officer now directly owns 252,577 shares in the company, valued at $47,582,981.03. The disclosure for this sale can be found here. Insiders have sold a total of 60,420 shares of company stock worth $11,308,477 over the last three months. Insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.